Wells Fargo raised the firm’s price target on Elevance Health to $600 from $557 and keeps an Overweight rating on the shares. Elevance Health’s Q1 results were strong, earnings quality appears high, and the story remains fairly clean, the analyst tells investors in a research note. The firm sees continued growth opportunities for Carelon and says improving MA growth and margins could support a higher multiple.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Elevance Health reports Medical membership totaled ~46.2M at March 31
- Elevance Health raises FY24 adjusted EPS view to greater than $37.20 per share
- Elevance Health reports Q1 adjusted EPS $10.64, consensus $10.53
- Notable companies reporting before tomorrow’s open
